The Ozempic pill is Novo Nordisk's oral semaglutide formulation for type-2 diabetes — the T2D-side companion to the oral Wegovy pill. On May 1 Novo officially retired the Rybelsus US brand and re-launched the same molecule as Ozempic Pill, leaning on the brand recognition of its blockbuster injectable. The reformulation improves absorption and bioavailability, allowing smaller tablets at lower mg doses (1.5/4/9 mg) with equivalent efficacy and safety to Rybelsus. Rybelsus continues outside the US.
The May 4 US launch landed alongside channel expansions through WW Med+ and GoodRx self-pay pricing ($149/$199/$299 per month by strength). The combined launch drove material market reactions: Lilly stock jumped 6.11% on Q1 2026 earnings with the Ozempic-pill announcement priced in, and Foundayo's IQVIA launch tracker hit 5,612 prescriptions in week three — well behind the Wegovy pill's run rate. The University of Utah's PapB enzyme paper on cyclic GLP-1-like peptides broke that week, adding chemistry context to the broader oral GLP-1 thread.
Stories here cover the Ozempic-pill launch, channel partnerships, and post-launch tracking. See #wegovy-pill, #oral-semaglutide, and #novo-nordisk.
Novo Nordisk announced May 1 that Rybelsus is being retired as a US brand and the molecule re-launches Monday May 4 as Ozempic Pill at 1.5/4/9 mg in 70,000+ pharmacies. Bloomberg and Fierce Pharma framed it as a marketing-driven move: same active ingredient as Rybelsus, but reformulated for improved absorption and bioavailability so smaller tablets achieve equivalent efficacy. Aligning the oral and injectable products under a single brand is meant to simplify prior authorizations and prescribing discussions, and to capitalize on Ozempic's recognition as Novo defends market share against Lilly's Foundayo. Rybelsus continues outside the US.
Novo Nordisk announced May 1 that Ozempic (semaglutide) tablets at 1.5 mg, 4 mg, and 9 mg will be available across 70,000+ U.S. pharmacies starting Monday, May 4, for adults with type 2 diabetes. The product is the only FDA-approved oral peptide GLP-1 medication cleared for both primary and secondary cardiovascular risk reduction in adults with T2D, manufactured end-to-end in the United States. Insured patients can access the pill for as little as $25 for up to a 3-month supply; self-pay patients face $149–$299/month depending on dose strength.
WeightWatchers announced May 1 that its Med+ platform and affiliated medical groups will begin offering Ozempic pill (oral semaglutide) for clinically eligible members with type 2 diabetes. Many eligible members can access the medication for as low as $25/month with pharmacy benefits. The expansion adds a once-daily oral GLP-1 alongside the existing Med+ portfolio of clinically supervised weight-management and metabolic-health treatments, giving WW a foothold in T2D care to complement its weight-loss positioning.
GoodRx announced May 1 that it has added self-pay access for the Ozempic pill, offering eligible patients with type 2 diabetes the medication at $149/month for the 1.5 mg dose, $199/month for 4 mg, and $299/month for 9 mg at participating pharmacies nationwide. The collaboration extends GoodRx's existing work across Novo Nordisk's full semaglutide portfolio, letting cash-paying patients bypass insurance complexity at the counter. The launch closes a transparency gap that has dogged consumer access to oral GLP-1 therapy.